All In Biotech

Drug Trial Radar · NCT06176508

Efficacy and Safety of HS-10374 Compared to Placebo in Adults With Active Psoriatic Arthritis

A Randomized, Double-blind, Placebo- and Comparator-controlled, Multicenter, Phase 2 Trial to Assess the Efficacy and Safety of HS-10374 in Adults With Active Psoriatic Arthritis

Last checked: Nov 19, 2026Latest source record: Jul 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 160 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

160

Planned (sponsor's estimate)

Start

Feb 26, 2024

Primary completion

Apr 28, 2026

Study completion Aug 28, 2026

Sponsor

Lead sponsor
Hansoh BioMedical R&D CompanyIndustry
Sponsor type
Industry
First posted
Dec 19, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study has been designed to explore the clinical efficacy and safety of HS-10374 in the treatment of active psoriatic arthritis. Additionally, this study is to find the optimal dosing for the future clinical development of HS-10374.

Conditions

  • Psoriatic Arthritis

Interventions

  • HS-10374Drug

    Administered orally QD for 16 weeks

  • HS-10374-matched placebo tabletsDrug

    Administered orally QD for 16 weeks

  • Tofacitinib 5Mg Tab,OralDrug

    Administered orally BID for 16 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of participants meeting American College of Rheumatology improvement of 20% (ACR20) response at Week 16Time frame: At week 16

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Huashan Hospital affiliated to Fudan University

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.